|
KMID : 1001020200180020124
|
|
Journal of Urologic Oncology
2020 Volume.18 No. 2 p.124 ~ p.139
|
|
|
Management of Patients With Advanced Prostate Cancer: Establishment of Treatment Guidelines Through Prostate Cancer Summit (PCAS) 2016 Composed of Korean Prostate Cancer Experts
|
|
Jang Chun-Tae
Kim Hyung-Joon
Kim Myung-Ki
Park Sung-Woo
Park Seung-Chol
Park Jae-Young
Lee Dong-Hyeon
Lee Seung-Hwan
Jeon Hwang-Gyun
Chung Jae-Hoon
Jeong Hyeon
Jo Moon-Ki
Hong Sung-Hoo
Kwak Cheol
Lee Ji-Youl
Kwon Dong-Deuk
Kim Choung-Soo
Jeon Seong-Soo
|
|
|
Abstract
|
|
|
Purpose: The Advanced Prostate Cancer Consensus Conference (APCCC) 2015 was based on topics with controversy in the field of advanced prostate cancer. To understand the Korean urologists perspective regarding the issues, we have conducted a questionnaire named Prostate Cancer Summit (PCAS) 2016, with 9 important subtopics.
Materials and Methods: Total 9 subtopics have been decided and questions were developed regarding each subtopic. The questions were based on that of APCCC 2015 and translated into Korean for better understanding. Total 51 panelists have voted online on 85 different questions.
Results: The survey concluded that testosterone should be measured as a diagnostic criterion for castration resistance prostate cancer (CRPC) and that consensus was reached on issues such as the use of androgen receptor pathway inhibitors in the treatment of predocetaxel and postdocetaxel in CRPC patients. In addition, 76% of the participants agreed that imaging tests were needed before new treatment in CRPC patients, and a majority of participants agreed that periodic imaging tests are necessary regardless of symptoms during treatment for CRPC. However, some issues, such as the use of prostate-specific antigen-based triggers for remediation in CRPC patients, the endocrine manipulation in nonmetastatic CRPC patients, and the onset of treatment in asymptomatic metastatic CRPC patients, were not agreed.
Conclusions: The results from PCAS 2016 has addressed some of the issues with controversy. Although the voting results are subjective, it will help guide treatment decisions in topics with less evidence.
|
|
|
KEYWORD
|
|
|
Advenced prostate cancer, CRPC, PCAS2016, APCCC2015
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|